Trial Profile
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary) ; Immunotherapies
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Cancer Insight
- 06 May 2021 Status changed from active, no longer recruiting to completed.
- 03 May 2021 Planned End Date changed from 1 Dec 2020 to 30 Oct 2021.
- 24 Mar 2020 Planned End Date changed from 1 May 2020 to 1 Dec 2020.